Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients

Authors: Li-Yang Hsu, Ying Ding, Jason Phua, Liang-Piu Koh, Douglas S Chan, Kay-Leong Khoo, Paul A Tambyah

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Invasive pulmonary aspergillosis (IPA) is a major cause of morbidity and mortality in patients with hematological malignancies in the setting of profound neutropenia and/or hematopoietic stem cell transplantation. Early diagnosis and therapy has been shown to improve outcomes, but reaching a definitive diagnosis quickly can be problematic. Recently, galactomannan testing of bronchoalveolar lavage (BAL) fluid has been investigated as a diagnostic test for IPA, but widespread experience and consensus on optical density (OD) cut-offs remain lacking.

Methods

We performed a prospective case-control study to determine an optimal BAL galactomannan OD cutoff for IPA in at-risk patients with hematological diagnoses. Cases were subjects with hematological diagnoses who met established definitions for proven or probable IPA. There were two control groups: subjects with hematological diagnoses who did not meet definitions for proven or probable IPA and subjects with non-hematological diagnoses who had no evidence of aspergillosis. Following bronchoscopy and BAL, galactomannan testing was performed using the Platelia Aspergillus seroassay in accordance with the manufacturer's instructions.

Results

There were 10 cases and 52 controls. Cases had higher BAL fluid galactomannan OD indices (median 4.1, range 1.1-7.7) compared with controls (median 0.3, range 0.1-1.1). ROC analysis demonstrated an optimum OD index cutoff of 1.1, with high specificity (98.1%) and sensitivity (100%) for diagnosing IPA.

Conclusions

Our results also support BAL galactomannan testing as a reasonably safe test with higher sensitivity compared to serum galactomannan testing in at-risk patients with hematological diseases. A higher OD cutoff is necessary to avoid over-diagnosis of IPA, and a standardized method of collection should be established before results can be compared between centers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Barnes PD, Marr KA: Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 2005, 20: 545-61. 10.1016/j.idc.2006.06.001.CrossRef Barnes PD, Marr KA: Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 2005, 20: 545-61. 10.1016/j.idc.2006.06.001.CrossRef
2.
go back to reference Von Eiff M, Roos N, Schlten R, Hesse M, Zuhlsdorf M, Loo van de J: Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995, 62: 341-7. 10.1159/000196477.CrossRefPubMed Von Eiff M, Roos N, Schlten R, Hesse M, Zuhlsdorf M, Loo van de J: Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995, 62: 341-7. 10.1159/000196477.CrossRefPubMed
3.
go back to reference De Pauw B, Walsh TH, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infections Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008, 46: 1813-21. 10.1086/588660.CrossRefPubMedPubMedCentral De Pauw B, Walsh TH, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infections Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008, 46: 1813-21. 10.1086/588660.CrossRefPubMedPubMedCentral
4.
go back to reference Hope WW, Walsh TJ, Denning DW: Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005, 5: 609-22. 10.1016/S1473-3099(05)70238-3.CrossRefPubMed Hope WW, Walsh TJ, Denning DW: Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005, 5: 609-22. 10.1016/S1473-3099(05)70238-3.CrossRefPubMed
5.
go back to reference Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E: Galactomannan in bronchoalveolar lavage fluid. A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008, 177: 27-34. 10.1164/rccm.200704-606OC.CrossRefPubMed Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E: Galactomannan in bronchoalveolar lavage fluid. A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008, 177: 27-34. 10.1164/rccm.200704-606OC.CrossRefPubMed
6.
go back to reference Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA: Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004, 42: 5517-22. 10.1128/JCM.42.12.5517-5522.2004.CrossRefPubMedPubMedCentral Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA: Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004, 42: 5517-22. 10.1128/JCM.42.12.5517-5522.2004.CrossRefPubMedPubMedCentral
7.
go back to reference Nguyen MH, Jaber R, Leather HL, Wingard JR, Staley B, Wheat LJ: Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol. 2007, 45: 2787-92. 10.1128/JCM.00716-07.CrossRefPubMedPubMedCentral Nguyen MH, Jaber R, Leather HL, Wingard JR, Staley B, Wheat LJ: Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol. 2007, 45: 2787-92. 10.1128/JCM.00716-07.CrossRefPubMedPubMedCentral
8.
go back to reference Husain S, Paterson DL, Studer SM, Crespo M, Pilewski J, Durkin M, Wheat JL, Johnson B, McLaughlin L, Bentsen C, McCurry KR, Singh N: Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007, 83: 1330-6. 10.1097/01.tp.0000263992.41003.33.CrossRefPubMed Husain S, Paterson DL, Studer SM, Crespo M, Pilewski J, Durkin M, Wheat JL, Johnson B, McLaughlin L, Bentsen C, McCurry KR, Singh N: Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007, 83: 1330-6. 10.1097/01.tp.0000263992.41003.33.CrossRefPubMed
9.
go back to reference Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, Cline CL, Rand KH, Schain D, Baz M, Nguyen MH: Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007, 45: 1759-65. 10.1128/JCM.00077-07.CrossRefPubMedPubMedCentral Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, Cline CL, Rand KH, Schain D, Baz M, Nguyen MH: Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007, 45: 1759-65. 10.1128/JCM.00077-07.CrossRefPubMedPubMedCentral
10.
go back to reference Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, Verbeken E, Verhoef G, Van Eldere J, Lagrou K: Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009, 49: 1688-93. 10.1086/647935.CrossRefPubMed Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, Verbeken E, Verhoef G, Van Eldere J, Lagrou K: Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009, 49: 1688-93. 10.1086/647935.CrossRefPubMed
11.
go back to reference Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ: Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007, 195: 455-66. 10.1086/510535.CrossRefPubMed Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ: Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007, 195: 455-66. 10.1086/510535.CrossRefPubMed
12.
go back to reference Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJA: Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008, 47: 1507-12. 10.1086/591531.CrossRefPubMed Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJA: Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008, 47: 1507-12. 10.1086/591531.CrossRefPubMed
Metadata
Title
Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients
Authors
Li-Yang Hsu
Ying Ding
Jason Phua
Liang-Piu Koh
Douglas S Chan
Kay-Leong Khoo
Paul A Tambyah
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-44

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.